iRadimed Corp. (NASDAQ:IRMD) shares saw unusually-high trading volume on Wednesday . Approximately 127,083 shares traded hands during trading, an increase of 58% from the previous session’s volume of 80,295 shares.The stock last traded at $17.28 and had previously closed at $17.28.

Several equities research analysts recently commented on IRMD shares. Roth Capital reaffirmed a “buy” rating on shares of iRadimed Corp. in a report on Tuesday, May 3rd. Zacks Investment Research raised iRadimed Corp. from a “hold” rating to a “strong-buy” rating and set a $19.00 price target for the company in a report on Wednesday, May 4th.

The company’s 50 day moving average is $19.27 and its 200-day moving average is $18.24. The company has a market capitalization of $186.44 million and a PE ratio of 25.10.

iRadimed Corp. (NASDAQ:IRMD) last released its quarterly earnings results on Friday, July 29th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.03. The company had revenue of $9.90 million for the quarter, compared to analysts’ expectations of $9.60 million. The business’s quarterly revenue was up 30.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.16 EPS. Equities analysts forecast that iRadimed Corp. will post $0.92 EPS for the current year.

In other iRadimed Corp. news, VP Steven M. Nardi sold 2,096 shares of iRadimed Corp. stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $17.11, for a total value of $35,862.56. Following the sale, the vice president now owns 1,996 shares of the company’s stock, valued at approximately $34,151.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Monty K. Allen sold 2,275 shares of iRadimed Corp. stock in a transaction that occurred on Tuesday, June 14th. The shares were sold at an average price of $20.00, for a total value of $45,500.00. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in iRadimed Corp. stock. Russell Frank Co acquired a new position in shares of iRadimed Corp. (NASDAQ:IRMD) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 95,112 shares of the company’s stock, valued at approximately $2,675,000. Russell Frank Co owned about 0.86% of iRadimed Corp. as of its most recent SEC filing.

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.